- Conditions
- Melanoma (Skin), Skin Cancer
- Interventions
- RAYS Intervention
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 3 Years to 7 Years
- Enrollment
- 843 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2030
- U.S. locations
- 2
- States / cities
- Salt Lake City, Utah • Morgantown, West Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 161
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Nonmelanoma Skin Cancer
- Interventions
- Electronic Brachytherapy
- Procedure
- Lead sponsor
- Xoft, Inc.
- Industry
- Eligibility
- 41 Years and older
- Enrollment
- 369 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 4
- States / cities
- Los Gatos, California • San Diego, California • Las Vegas, Nevada
- Conditions
- Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma, Pancreatic Cancer, Breast Cancer (HR+HER2-)
- Interventions
- LY3300054, Ramucirumab, Abemaciclib, Merestinib, LY3321367
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee • Houston, Texas • San Antonio, Texas
- Conditions
- Skin Lesion
- Interventions
- Photos
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Advanced Melanoma
- Interventions
- Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice
- Drug
- Lead sponsor
- Immunocore Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 19 more
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Apocrine Carcinoma, Carcinoma Arising From Cylindroma, Carcinoma Arising From Spiradenoma, Digital Papillary Adenocarcinoma, Endocrine Mucin-Producing Sweat Gland Carcinoma, Extramammary Paget Disease, Extraocular Sebaceous Carcinoma, Hidradenocarcinoma, Malignant Sweat Gland Neoplasm, Merkel Cell Carcinoma, Microcystic Adnexal Carcinoma, NK-Cell Lymphoma, Unclassifiable, Papillary Adenocarcinoma, Porocarcinoma, Primary Cutaneous Mucinous Carcinoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Merkel Cell Carcinoma, Refractory Mycosis Fungoides, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Skin Squamous Cell Carcinoma, Refractory T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Signet Ring Cell Adenocarcinoma, Skin Adenoid Cystic Carcinoma, Skin Adnexal Carcinoma, Skin Basal Cell Carcinoma, Skin Basosquamous Cell Carcinoma, Skin Keratoacanthoma, Skin Squamous Cell Carcinoma, Squamoid Eccrine Ductal Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Sweat Gland Carcinoma, Trichilemmal Carcinoma, Vulvar Squamous Cell Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Laboratory Biomarker Analysis, Nivolumab, Positron Emission Mammography, Talimogene Laherparepvec
- Procedure · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 36
- States / cities
- Los Angeles, California • Orange, California • Pasadena, California + 28 more
- Conditions
- Advanced Cutaneous Melanoma
- Interventions
- Not listed
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,411 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 24
- States / cities
- Gilbert, Arizona • Hot Springs, Arkansas • Encinitas, California + 20 more
- Conditions
- Melanoma (Skin)
- Interventions
- therapeutic autologous lymphocytes, Use of an artificial antigen presenting cell (aAPC) to generate CTL, GM-CSF, Irradiation of cutaneous tumor lesion
- Biological · Genetic · Drug + 1 more
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma
- Interventions
- PF-08046033
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 11
- States / cities
- Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 2 more
- Conditions
- Skin Cancer, Non-melanoma Skin Cancer, Sun Damaged Skin, Actinic Keratosis
- Interventions
- Levulan® Kerastick®, BLU-U Blue Light Photodynamic Therapy
- Drug
- Lead sponsor
- Medical Dermatology Specialists
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Melanoma
- Interventions
- Dabrafenib, Trametinib, Trametinib placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 423 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 15 more
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8
- Interventions
- Immunohistochemistry Staining Method, Mohs Surgery
- Diagnostic Test · Procedure
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor, Metastatic Melanoma
- Interventions
- ANV419
- Drug
- Lead sponsor
- Anaveon AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 6 more
- Conditions
- Metastatic Melanoma, Recurrent Cutaneous Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Interventions
- Ibrutinib, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Sacramento, California • Aurora, Colorado + 9 more
- Conditions
- Malignant Melanoma
- Interventions
- IMCgp100
- Drug
- Lead sponsor
- Immunocore Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Interventions
- TBio-4101, Pembrolizumab
- Biological · Drug
- Lead sponsor
- Turnstone Biologics, Corp.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 11
- States / cities
- Irvine, California • Hollywood, Florida • Miami, Florida + 8 more
- Conditions
- Melanoma, Metastatic Melanoma, Advanced Solid Tumor, Hepatocellular Carcinoma
- Interventions
- Observational study with no interventions
- Other
- Lead sponsor
- Replimune, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Non-small Cell Lung Carcinoma (NSCLC), Melanoma, Bladder Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer
- Interventions
- CM-24 (MK-6018), Pembrolizumab (MK-3475)
- Biological
- Lead sponsor
- Famewave Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Los Angeles, California • New Haven, Connecticut
- Conditions
- Metastatic Liver Cancer, Ocular Melanoma, Cutaneous Melanoma
- Interventions
- Melphalan, Percutaneous Hepatic Perfusion
- Drug · Device
- Lead sponsor
- Delcath Systems Inc.
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 6
- States / cities
- Santa Monica, California • Englewood, Colorado • Tampa, Florida + 3 more
- Conditions
- Pancreatic Cancer
- Interventions
- 16S rRNA gene sequencing assay
- Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 55 Years to 74 Years
- Enrollment
- 732 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1992 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Melanoma
- Interventions
- Completion Lymphadenectomy, Monitoring with nodal ultrasound
- Procedure
- Lead sponsor
- Saint John's Cancer Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,939 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2019
- U.S. locations
- 39
- States / cities
- San Diego, California • Santa Monica, California • Colorado Springs, Colorado + 31 more
- Conditions
- BRAF or NRAS Mutant Metastatic Melanoma
- Interventions
- MEK162
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 10
- States / cities
- Fayetteville, Arkansas • Tampa, Florida • Portland, Oregon + 3 more
- Conditions
- Stage IV Melanoma
- Interventions
- Antineoplaston therapy (Atengenal + Astugenal)
- Drug
- Lead sponsor
- Burzynski Research Institute
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-melanoma Skin Cancer (NMSC)
- Interventions
- MC1R genotyping, MC1R Testing Website, Baseline Survey
- Genetic · Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York